AbbVie, Teva Hit With 2 More Niaspan Pay-For-Delay Suits

Law360, New York (May 1, 2013, 1:36 PM EDT) -- AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were hit Tuesday with a pair of putative antitrust class actions challenging a pay-for-delay deal that allegedly harmed consumers by keeping a generic version of AbbVie’s cholesterol drug Niaspan off the market.

The city of Providence, R.I., and a painters union's benefits fund lodged separate putative class actions, both alleging that an agreement between AbbVie and Teva kept a less-expensive generic version of Niaspan off the market for several years and, in effect, harmed competition and consumers who have...
To view the full article, register now.